Drug news
Reyataz and Cobicistat filed with FDA for HIV - BMS/Gilead
BMS has filed for FDA approval of a fixed-dose combination of Reyataz (atazanavir) and Cobicistat, from Gilead Sciences, for the treatment of HIV-1 infection. The application is based on a Phase III study comparing the efficacy and safety of Cobicistat-boosted Reyataz with Reyataz alone in treatment-na�ve patients infected with HIV-1.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.